Miravant Medical Technologies Inc. suffered a 75.6 percent stock drop Monday on negative Phase III data of an investigational drug to treat vision loss.

Miravant's SnET2 Fails Phase III; Stock Price Drops 75 Percent

Jan. 15, 2002

By Aaron Lorenzo

No Comments

Miravant Medical Technologies Inc. suffered a 75.6 percent stock drop Monday on negative Phase III data of an investigational drug to treat vision loss.

IGEN Wins $505M From Roche In Court; Roche Plans To Appeal

Jan. 14, 2002

By Aaron Lorenzo

No Comments

IGEN Wins $505M From Roche In Court; Roche Plans To Appeal

Jan. 14, 2002

By Aaron Lorenzo

No Comments

Enzon, Inhale Enter Broad Deal On Pegylation, Licensing, Lawsuit

Jan. 9, 2002

By Aaron Lorenzo

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Articles by Aaron Lorenzo

Syrrx’s Structural Proteomics At Heart Of Pharmacia Alliance

Triangle Plans NDA For One Drug, Discontinues Another

Triangle Plans NDA For One Drug, Discontinues Another

LION Purchasing NetGenics In Stock Deal Worth $17.6M

LION Purchasing NetGenics In Stock Deal Worth $17.6M

Miravant's SnET2 Fails Phase III; Stock Price Drops 75 Percent

Miravant's SnET2 Fails Phase III; Stock Price Drops 75 Percent

IGEN Wins $505M From Roche In Court; Roche Plans To Appeal

IGEN Wins $505M From Roche In Court; Roche Plans To Appeal

Enzon, Inhale Enter Broad Deal On Pegylation, Licensing, Lawsuit

Today's news in brief

Today's news in brief

Ionis notches Arrowhead win; Tryngolza cleared for FCS

NRP1 is NGF/TrkA partner in crime in pain signaling

STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space